Marival Bermejo

Prof. Dr. Marival Bermejo

Department Engineering Pharmacy Section, Miguel Hernandez University, San Juan de Alicante, 03550 Alicante, Spain
orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2003 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
NKNehal A. Kasim
Nehal A. Kasim
MWMarc Whitehouse
Marc Whitehouse
CRChandrasekharan Ramachandran
Chandrasekharan Ramachandran
Marival BermejoMarival Bermejo
Marival Bermejo
HLHans Lennernäs
Hans Lennernäs
GAGordon L. Amidon
Gordon L. Amidon

3 October 2006 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
TTToshihide Takagi
Toshihide Takagi
CRChandrasekharan Ramachandran
Chandrasekharan Ramachandran
Marival BermejoMarival Bermejo
Marival Bermejo
SYShinji Yamashita
Shinji Yamashita
LYLawrence X. Yu
Lawrence X. Yu
GAGordon L. Amidon
Gordon L. Amidon

10 March 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
ILIsabel Lozoya-Agullo
Isabel Lozoya-Agullo
FAFrancisca Araújo
Francisca Araújo
Isabel Gonzalez-AlvarezIsabel Gonzalez-Alvarez
Isabel Gonzalez-Alvarez
MMMatilde Merino-Sanjuán
Matilde Merino-Sanjuán
MGMarta Gonzalez-Alvarez
Marta Gonzalez-Alvarez
Bruno SarmentoBruno Sarmento
Bruno Sarmento

1 March 2004 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
Marival BermejoMarival Bermejo
Marival Bermejo
AAAlex Avdeef
Alex Avdeef
ARAna Ruiz
Ana Ruiz
Ricardo Nalda-MolinaRicardo Nalda-Molina
Ricardo Nalda-Molina
JRJeffrey A. Ruell
Jeffrey A. Ruell
VMVirginia Merino
Virginia Merino

1 February 2008 in Journal of Pharmaceutical Sciences
Verified
Journal Article
Open access
PDF file
ARAna Ruiz-Garcia
Ana Ruiz-Garcia
Marival BermejoMarival Bermejo
Marival Bermejo
AMAaron Moss
Aaron Moss
VCVicente G. Casabo
Vicente G. Casabo
The aim of this current review is to summarize the present status of pharmacokinetics in Drug Discovery. The review is structured into four sections. The first section is a general overview of what we understand by pharmacokinetics and the different LADMET aspects: Liberation, Absorption, Distribution, Metabolism, Excretion, and Toxicity. The second section highlights the different computational or in silico approaches to estimate/predict one or several aspects of the pharmacokinetic profile of a discovery lead compound. The third section discusses the most commonly used in vitro methodologies. The fourth and last section examines the various approaches employed towards the pharmacokinetic assessment of discovery molecules; including all the LADME processes, discussing the different mathematical methodologies available to establish the PK profile of a test compound; what the main differences are and what should be the criteria for using one or another mathematical approach. The major conclusion of this review is that the use of the appropriate preclinical assays has a key role in the long‐term viability of a pharmaceutical company since applying the right tools early in discovery will play a key role in determining the company's ability to discover novel safe and effective therapeutics to patients as quickly as possible. © 2007 Wiley‐Liss, Inc. and the American Pharmacists Association J Pharm Sci 97:654–690, 2008

4 August 2017 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
Bart HensBart Hens
Bart Hens
YTYasuhiro Tsume
Yasuhiro Tsume
Marival BermejoMarival Bermejo
Marival Bermejo
PPPaulo Paixão
Paulo Paixão
MKMark J. Koenigsknecht
Mark J. Koenigsknecht
GAGordon L. Amidon
Gordon L. Amidon